Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,770

Synthetic Cannabinoid Drug For Covid-19 Approved For Phase-1 Clinical Trials

August 2020… “As Covid-19 continues to take lives on a daily basis, the search is ongoing for solutions that might prevent, cure or treat the deadly disease. In recent months, some have pointed to cannabis as a possible treatment for severe cases of the Covid-19 — pointing specifically towards the cannabinoid CBD, one of cannabis’ main chemical ingredients. And some research has suggested that this cannabinoid could be helpful. Now, a synthetic cannabinoid drug, ARDS-003, has been given approval by the FDA to begin phase-1 clinical trials. ARDS-003 is an injectable drug designed to help with acute respiratory distress syndrome (ARDS), a serious syndrome that occurs in severe cases of the novel coronavirus. This syndrome can be triggered during a cytokine storm, a dangerous over-elevation of cytokines. Cytokines are proteins which signal the body to produce more inflammation. While inflammation is a normal and healthy part of immune responses, when too much of it is produced, it can lead to serious and deadly problems like organ failure and ARDS. ”.

Dr. Ann Aerts, MD — Novartis Foundation — Transforming The Health Of Low-Income Populations Globally

Dr. Ann Aerts MD, Head of the Novartis Foundation and Member of the US National Academies of Medicine Commission on Healthy Longevity.

Dr. Ann Aerts, M.D. is Head of the Novartis Foundation, an organization committed to transforming the health of low-income populations, by leveraging the power of data, digital technology and artificial intelligence (AI) to re-imagine health and care around the world.

Dr. Aerts holds a Degree in Medicine, a Masters in Public Health from the University of Leuven, Belgium, and a Degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp, Belgium.

Dr. Aerts is passionate about improving population health through data, digital health and AI, chairs the Broadband Commission for Sustainable Development Working Group on Digital and AI in Health and is a member of the International Advisory Board of the Commonwealth Centre for Digital Health.

In 2018, Dr. Aerts served as a member of the US National Academies of Science Engineering and Medicine Committee on Improving the Quality of Health Care Globally and sits on the US National Academies of Medicine Commission on Healthy Longevity. Dr. Aerts has authored numerous publications on digital health, innovative approaches and multi-sector partnerships to address global health challenges.

Continue reading “Dr. Ann Aerts, MD — Novartis Foundation — Transforming The Health Of Low-Income Populations Globally” | >

Comprehensive Genetic Map Reveals Circuitry of 30,000 Human Disease Regions

Analysis reveals genetic control elements that are linked to hundreds of human traits.

Twenty years ago this month, the first draft of the human genome was publicly released. One of the major surprises that came from that project was the revelation that only 1.5 percent of the human genome consists of protein-coding genes.

Over the past two decades, it has become apparent that those noncoding stretches of DNA, originally thought to be “junk DNA,” play critical roles in development and gene regulation. In a new study published on February 32021, a team of researchers from MIT has published the most comprehensive map yet of this noncoding DNA.